Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1979 1
1980 1
1981 1
1982 1
1989 1
1999 2
2001 1
2007 1
2008 1
2009 3
2010 5
2011 5
2012 5
2013 8
2014 5
2015 2
2016 6
2017 2
2018 5
2019 8
2020 5
2021 11
2022 10
2023 7
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.
Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, Baumane K, Agarwal S, Oleksy P, Reichstein DA, Patel SS, Ernest J, Dégi R, Gupta V, Kishino G, Kamei M, Loganathan S; INSIGHT Study Group. Bressler SB, et al. JAMA Ophthalmol. 2024 Oct 1;142(10):952-960. doi: 10.1001/jamaophthalmol.2024.3458. JAMA Ophthalmol. 2024. PMID: 39264599 Free PMC article. Clinical Trial.
Retinal Vein Occlusion.
Sawada O, Ohji M. Sawada O, et al. Dev Ophthalmol. 2016;55:147-53. doi: 10.1159/000438971. Epub 2015 Oct 26. Dev Ophthalmol. 2016. PMID: 26501219 Review.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
TRAFFIC ACCIDENT-RELATED OPEN GLOBE INJURIES.
Okamoto Y, Morikawa S, Okamoto F, Mitamura Y, Ishikawa H, Ueda T, Sakamoto T, Sugitani K, Sawada O, Mori J, Takamura Y, Oshika T. Okamoto Y, et al. Among authors: sawada o. Retina. 2019 Apr;39(4):779-785. doi: 10.1097/IAE.0000000000002012. Retina. 2019. PMID: 29252975
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
Ichiyama Y, Matsumoto R, Obata S, Sawada O, Saishin Y, Kakinoki M, Sawada T, Ohji M. Ichiyama Y, et al. Among authors: sawada o. PLoS One. 2022 Dec 21;17(12):e0278951. doi: 10.1371/journal.pone.0278951. eCollection 2022. PLoS One. 2022. PMID: 36542626 Free PMC article.
86 results